Eris Lifesciences: Stock in focus after company partners with Natco Pharma to launch Semaglutide in IndiaEris Lifesciences: Stock in focus after company partners with Natco Pharma to launch Semaglutide in India

Introduction

Leading Indian branded formulations company announced partnership with Natco Pharma to commercialise semaglutide in India, with launch planned after CDSCO approval in March 2026.

Also Read: Waaree Energies in green on securing 500MW solar module order; check details

Share price movement of Eris Lifesciences

On February 25, 2026, Eris Lifesciences Ltd opened at ₹1,390.00, up 0.39% from its previous close of ₹1,384.60. The stock reached a high of ₹1,400.00 (1.11%) and a low of ₹1,368.70. By 11:18 AM, it traded at ₹1,369.30, a 1.11% decrease, with a market cap of ₹18,652.18 crore.

Eris Partners Natco for Semaglutide

Eris Lifesciences Limited announced a strategic partnership with Natco Pharma Limited for commercialisation of semaglutide in India. The collaboration targets expansion in diabetes and metabolic care segment nationwide.

Natco Pharma received approval from the Central Drugs Standard Control Organisation to manufacture generic semaglutide for the Indian market. The companies expect to launch the product in March 2026.

Semaglutide is a GLP-1 receptor agonist indicated for Type 2 diabetes management. The partnership combines Eris Lifesciences commercial presence with Natco Pharma manufacturing and regulatory capabilities.

Stock performance of Eris Lifesciences for period of 1 week, 6 months, and 1 year

Eris Lifesciences Ltd delivered a 2.97% return over the past week and declined 23.1% over the past 6 months. The stock gained 12.0% over the past year.

Also Read: One Mobikwik Systems jumps 13% after subsidiary gets BSE nod to launch broking operations

Shareholding pattern of Eris Lifesciences

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	54.90%	54.90%	54.80%
FII	6.90%	7%	8%
DII	20.30%	19.40%	18.20%
Public	18.00%	18.60%	18.60%

About Eris Lifesciences

Eris Lifesciences Ltd (NSE: ERIS) is an Indian pharmaceutical company focused on branded formulations across diabetes, cardiovascular, dermatology, oncology, and other specialty segments.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs